|
Program Overview:
Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy
decreases cardiovascular morbidity and mortality in patients with heart
failure (HF). Evidence-based HF guidelines support the titration of
RAASi to achieve target doses to optimize treatment benefits. However,
RAASi also increases the risk of hyperkalemia. Hyperkalemia is an
electrolyte disorder characterized by elevated levels of serum
potassium; if left untreated, hyperkalemia can lead to fatal cardiac
arrhythmias, cardiac arrest, and sudden death. Hyperkalemia is a barrier
to optimization of RAASi therapy in patients with HF; despite strong
evidence for cardiorenal protective effects of RAASi, unfortunately
down-titration or discontinuation of RAASi treatment is a common
strategy to manage hyperkalemia in routine clinical practice; these
actions place HF patients at increased risk of major adverse clinical
events. Novel potassium binders effectively and safely lower serum
potassium, potentially enabling HF patients to remain on optimal RAASi
therapy. Therefore, in this educational initiative, a faculty of experts —
cardiologists Dr. Mikhail Kosiborod, Dr. Mark Petrie, and Dr. Shelley
Zieroth, and nephrologist Dr. David Cherney — will explain, through
lecture and "real-world " case presentation, best practices for managing
hyperkalemia with potassium binders and facilitating maintenance of
cardiorenal protection with RAASi.
|
|
Educational Objectives:
Upon completion of this activity, participants should be able to:
Describe the relationship between suboptimal RAASi therapy and poor cardiorenal outcomes
Explain clinical data with, and demonstrate prudent use of novel potassium binders
Identify patients who would benefit from anti-hyperkalemia medications
Target Audience:
This educational activity is intended for healthcare professionals who manage patients with hyperkalemia
Accreditation & Credit Designation:
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s) ™. Physicians should claim only the credit commensurate with the extent
of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits ™
through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits ™ from organizations accredited by the ACCME.
Educational Grant: Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.
Disclosure Statement:
Voxmedia strives to ensure fair-balance, independence, objectivity,
and scientific rigor in all directly or jointly sponsored educational
activities. All prospective faculty are required to disclose to Voxmedia
all financial relationships for the preceding 24 months (1) with any
commercial interest producing, marketing, re-selling, or distributing
health care goods or services consumed by, or used on, patients AND
(2) with any commercial supporters prior to participating in the
planning of an activity or developing content. Only after Voxmedia
mitigates all financial relationships may faculty receive approval to
participate, and are expected to contribute evidence-based material.
Faculty are required to indicate areas of their presentation that are
based on professional opinion vs. guidelines, meta-analysis. All
information submitted will be peer-reviewed. The intent of this
disclosure is not to prevent faculty from participating, but rather to
provide learners with information on which they can make their own
judgment of commercial bias. Voxmedia will disclose to learners that
all relevant financial relationships have been mitigated in either
written materials, visually and/or verbally. It remains for the audience
to determine whether the speaker s interests or relationships may
influence the presentation. Speakers must make a
meaningful disclosure to the audience of their
discussions of any unlabeled or investigational
use(s) of drugs or devices.
Random-Drawing Contest Rules and Regulations*
1. Drawing is open to all licensed medical professionals 18 years of age and older who are legal residents of the United
States and who attend to-the-end Voxmedia’s CME Symposium ‘Managing Hyperkalemia in Heart Failure: Overcoming
Roadblocks with Best Practices’ (“CME Symposium”) on November 17, 2024 at the Hyatt Regency McCormick Place,
2233 S. Dr. Martin Luther King Jr. Drive, Chicago, Illinois. Drawing is promoted by Voxmedia LLC dba
CMEPlanet.com, 1 Bethany Road, Hazlet, NJ 07730.
2. NO PURCHASE NECESSARY. To be entered into the drawing, you must check-in on-site for the CME Symposium prior
to 6:00 PM on November 17, 2024, and be present at time of drawing approx. 7:45 PM on November 17, 2024.
3. Four (4) total prizes will be awarded in the form of $150.00 Amazon Gift Cards to four (4) randomly-selected winners.
One prize per winner. Prize is non-transferable and non-assignable. No substitution of prizes is permitted except by
Voxmedia. Prize is not redeemable for cash. The odds of winning are dependent upon the number of eligible entries
received. Voxmedia reserves the right to require proof of medical license and jurisdiction of residence prior to awarding
any prize. Voxmedia/ CMEPlanet.com reserves the right to use the winner’s name, practice/affiliation, city/state and
photograph for publicity purposes without further permission or compensation. All federal, state, and local laws and
regulations apply. Void where prohibited.
|